STAT December 17, 2025
Sarepta Therapeutics’ Doug Ingram has taken on unnecessary risks for Duchenne patients
Doug Ingram of Sarepta Therapeutics is my pick for the Worst Biopharma CEO of 2025.
He was an easy selection, but unlike some cases in the past, this pick brought me no joy, because the circumstances that earned Ingram this dishonor are tinged with sadness.
In 2024, Ingram moved aggressively,...







